Kenya Moves Toward Vaccine Self-Reliance with Locally Made Trials Backed by World Bank
Kenya’s BioVax Institute, backed by a US$62 million World Bank package, will begin trials by 2027 on locally made pneumonia and typhoid vaccines, aiming to cut reliance on imports and align with Africa’s push for regional vaccine manufacturing.
